Search

Your search keyword '"C, Dubos-Arvis"' showing total 27 results

Search Constraints

Start Over You searched for: Author "C, Dubos-Arvis" Remove constraint Author: "C, Dubos-Arvis"
Sorry, I don't understand your search. ×
27 results on '"C, Dubos-Arvis"'

Search Results

1. Vemurafenib in non-small-cell lung cancer patients with BRAF

2. Mésothéliomes malins et mutations constitutionnelles du gène BAP1

Catalog

Books, media, physical & digital resources

3. Use of archival versus newly collected tumor samples for assessing PD-L1 expression and overall survival: an updated analysis of KEYNOTE-010 trial

4. Efficacité et tolérance cérébrale d’une chimiothérapie par platine/pemetrexed/bévacizumab chez des patients atteints de carcinome bronchique non à petites cellules (CBNPC) non épidermoïde

5. [Malignant mesothelioma and constitutional BAP1 gene mutations]

6. Long-term follow-up in the KEYNOTE-010 study of pembrolizumab (pembro) for advanced NSCLC, including in patients (pts) who completed 2 years of pembro and pts who received a second course of pembro

7. Activité de l’osimertinib dans les méningites carcinomateuses des cancers non à petites cellules (CPNPC) avec mutation activatrice de l’EGFR ayant déjà bénéficié d’un traitement par inhibiteur tyrosine-kinase (TKI) de l’EGFR

8. Long-term survival in patients (pts) with advanced NSCLC in the KEYNOTE-010 study overall and in pts who completed two years of pembrolizumab (pembro)

10. Time-to-treatment failure (TTF) with first-line afatinib (A) vs gefitinib (G) in patients (pts) with EGFR mutation-positive (EGFRm+) advanced non-small-cell lung cancer (NSCLC): Randomized phase IIb LUX-lung 7 (LL7) trial

11. Pembrolizumab (pembro) vs docetaxel (doce) for previously treated, PD-L1–expressing NSCLC: Updated outcomes of KEYNOTE-010

12. 1038 EGFR-mutation improves 1-year survival in patients with adenocarcinoma followed in French general hospitals in 2010

13. Neoadjuvant durvalumab for resectable non-small-cell lung cancer (NSCLC): results from a multicenter study (IFCT-1601 IONESCO).

14. Efficacy and Safety of Anti-PD-1 Immunotherapy in Patients With Advanced NSCLC With BRAF, HER2, or MET Mutations or RET Translocation: GFPC 01-2018.

15. Somatic profile in lung cancers is associated to reproductive factors in never-smokers women: Results from the IFCT-1002 BioCAST study.

16. Vemurafenib in non-small-cell lung cancer patients with BRAF V600 and BRAF nonV600 mutations.

17. Potential Antiangiogenic Treatment Eligibility of Patients with Squamous Non-Small-Cell Lung Cancer: EPISQUAMAB Study (GFPC 2015-01).

18. [Malignant mesothelioma and constitutional BAP1 gene mutations].

19. Use of archival versus newly collected tumor samples for assessing PD-L1 expression and overall survival: an updated analysis of KEYNOTE-010 trial.

20. Safety of combined PD-1 pathway inhibition and radiation therapy for non-small-cell lung cancer: A multicentric retrospective study from the GFPC.

21. Efficacy of Osimertinib in EGFR-Mutated Non-Small Cell Lung Cancer with Leptomeningeal Metastases Pretreated with EGFR-Tyrosine Kinase Inhibitors.

22. Oxaliplatin-induced bronchiolitis obliterans organizing pneumonia following hyperthermic intraperitoneal chemotherapy.

23. Non-Small-Cell Lung Cancer (NSCLC) Harboring ALK Translocations: Clinical Characteristics and Management in a Real-Life Setting: a French Retrospective Analysis (GFPC 02-14 Study).

24. Off-Label Use of Crizotinib as a Neoadjuvant Treatment for a Young Patient When Conventional Chemotherapy Gave No Benefits in Stage IIIA Non-Small Cell Lung Cancer.

25. Assessment of multi-contaminant exposure in a cancer treatment center: a 2-year monitoring of molds, mycotoxins, endotoxins, and glucans in bioaerosols.

26. Erlotinib-associated rash in patients with EGFR mutation-positive non-small-cell lung cancer treated in the EURTAC trial.

27. Harmonizing SUVs in multicentre trials when using different generation PET systems: prospective validation in non-small cell lung cancer patients.